=== chr6:32053637C>G Genomic Analysis Report ===


#VARIANT INFO:


DETAILED VARIANT INFORMATION:
=============================
• rsID: rs61745355
• Chromosome: 6
• Position: 32053637
• Reference Allele (REF): C
• Alternative Allele (ALT): G
• Genotype: 1|0
• Quality Score: N/A
• Gene Names: TNXB
• Databases: rs61745355, COSV64480230

CLINICAL ANNOTATIONS:
====================
• ClinVar Significance: uncertain_significance, benign
• ACMG Classification: Uncertain significance
• OMIM: True

POPULATION FREQUENCIES:
======================
• gnomAD Allele Frequency: 0.0002128
• gnomADg Allele Frequency: 0.00011169999999999999
• 1KG Frequency: N/A

SEQUENCING DATA:
================
• Depth (DP): N/A
• Allelic Depth (AD): [-1, -1]


# GWAS INFO
GWAS ASSOCIATIONS DATABASE:
GWAS_EFO_0002690: systemic lupus erythematosus - An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.|A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
GWAS_EFO_0010443: triacylglycerol 58:9 measurement - The quantification of triacylglycerol 58:9 levels in some body fluid, used as a biomarker for disease.
GWAS_EFO_0008579: risk-taking behaviour - The tendency to take risks. Risk-taking behaviour is a characteristic of several psychiatric disorders such as ADHD and bipolar disorder, as well as problem behaviours such as smoking and drug abuse.
GWAS_EFO_0004842: eosinophil count - Is a quantification of eosinphils in blood.|The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter.
GWAS_EFO_0005090: basophil count - quantification of basophils in the blood|The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter.
GWAS_EFO_0004833: neutrophil count - Is a quantification of neutrophils in blood.|The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter.
GWAS_EFO_0004980: appendicular lean mass - Appendicular lean mass is a measurement of skeletal strength of lower limbs and is used as a predictive measure of hip fracture.
GWAS_EFO_0004308: leukocyte count - The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
GWAS_EFO_0007937: blood protein measurement - quantification of the levels of some protein in a blood sample
GWAS_EFO_0004875: mathematical ability - Is the mental process necessary to acquire knowledge or skill in the measurement, properties, and relationships of quantities and sets, using numbers and symbols (mathematics)
GWAS_EFO_0007869: wellbeing measurement - quantification of some aspect of wellbeing such as life satisfaction or emotional wellbeing, usually self-reported and quantified through the use of a structured questionnaire
GWAS_EFO_0008402: susceptibility to cold sores measurement - Quantification of an individual's susceptibility to cold sores, vesicular lesions of the lips and mouth caused by another member of the human herpesvirus family, herpes simplex virus type 1 (HSV-1)
GWAS_EFO_0008401: susceptibility to shingles measurement - Quantification of an individual's susceptibility to shingles, a pinaful rash resultin from reactivation of latent Varicella zoster virus infection within a dorsal root ganglion, typically occuring in later life.
GWAS_EFO_0007006: depressive symptom measurement - quantification of the existence and severity of depressive symptoms, usually via a questionnaire such as the Center for Epidemiological Studies Depression Scale (CES-D) 
GWAS_EFO_0007660: neuroticism measurement - Quantification of some aspect of neuroticism or neurotic behaviour, such as severity or frequency of neurotic behaviour. This is usually assessed via a standardised questionnaire.
GWAS_EFO_0004984: complement C4 measurement - Complement C4 measurement is a quantification of the C4 glycoprotein, typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes.
GWAS_EFO_0007984: platelet component distribution width - The determination of the amount of platelet shape changes present in a sample. [ NCI ]|Measure of variation in platelet size.
GWAS_EFO_0000249: obsolete_Alzheimer's disease - A dementia that results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting in late middle age and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid. It is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability.|A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.|A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)|A dementia which is an incurable disease of unknown cause, starting in late middle age or in old age, that results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood, that leads in advanced cases to a profound decline in cognitive and physical functioning, and that is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.
GWAS_HP_0000155: Oral ulcer - Erosion of the mucous mebrane of the mouth with local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue.
GWAS_EFO_0000692: obsolete_schizophrenia - A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.|A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
GWAS_EFO_0003756: autism spectrum disorder - A spectrum of developmental disorders that includes autism, and Asperger syndrome. Signs and symptoms include poor communication skills, defective social interactions, and repetitive behaviors.|A pervasive developmental disease that is a spectrum of psychological conditions characterized by widespread abnormalities of social interactions and communication, as well as severely restricted interests and highly repetitive behavior.|Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.|Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (DSM, 1994)
GWAS_EFO_0000180: HIV-1 infection - The type species of lentivirus and the etiologic agent of acquired immunodeficiency syndrome (AIDS). It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
GWAS_EFO_0004256: neuromyelitis optica - A syndrome characterized by acute OPTIC NEURITIS in combination with acute MYELITIS, TRANSVERSE. Demyelinating and/or necrotizing lesions form in one or both optic nerves and in the spinal cord. The onset of optic neuritis and myelitis may be simultaneous or separated by several months. (J Neurol Neurosurg Psychiatry 1996 Apr;60(4):382-387).|Neuromyelitis optica (NMO) and NMO spectrum disorders are inflammatory demyelinating diseases of the central nervous system characterized mainly by attacks of uni- or bilateral optic neuritis (ON) and acute myelitis.
GWAS_EFO_0009584: AQP4-IgG-positive neuromyelitis optica - A subtype of neuromyelitis optica caused by an autoimmune aquaporin-4 channelopathy, due to presence of circulating autoantibodies against aquaporin 4.
GWAS_EFO_0008354: cognitive function measurement - quantification of some aspect of cognitive function
GWAS_EFO_0001071: lung carcinoma - A carcinoma that arises from epithelial cells of the lung
GWAS_EFO_0006527: smoking status measurement - self-reported binary measure, used to denote whether an individual is currently or has ever been a smoker
GWAS_EFO_0000708: squamous cell lung carcinoma - A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.|In DO this is classified as nscLC, but this leads to logical issues as we have a distinct class for squamous nscLC
GWAS_EFO_0006335: systolic blood pressure - The blood pressure during the contraction of the left ventricle of the heart.
GWAS_EFO_0000537: hypertension - Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.|Persistently high systemic arterial blood pressure. Based on multiple readings (blood pressure determination), hypertension is currently defined as when systolic pressure is consistently greater than 140 mm Hg or when diastolic pressure is consistently 90 mm Hg or more.
GWAS_EFO_0006336: diastolic blood pressure - The blood pressure after the contraction of the heart while the chambers of the heart refill with blood.
GWAS_EFO_0004784: self reported educational attainment - A measure of educational progress reported using a questionnaire based approach, often used as a proxy for cognitive performance as the two are correlated.
GWAS_EFO_0004339: body height - The distance from the sole to the crown of the head with body standing on a flat surface and fully extended.
GWAS_EFO_0005243: myeloperoxidase measurement - quantification of the enzyme myeloperoxidase in the blood, for example as an indicator of coronary artery disease
GWAS_EFO_0001061: cervical carcinoma - A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.
GWAS_EFO_0004509: hemoglobin measurement - hemoglobin levels|Hemoglobin measurement is a measure of the quantity of the metallo protein hemoglobin in blood often used in the diagnosis of anaemia.
GWAS_EFO_0003778: psoriatic arthritis - Joint inflammation associated with psoriasis.|A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
GWAS_EFO_0000274: atopic eczema - A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
GWAS_EFO_0007924: tonsillectomy risk measurement - Quantification an individual's risk of undergoing tonsillectomy. Some individuals experience recurrent, severe tonsillitis and massive hypertrophy of the tonsils in which case surgical removal of the tonsils may be considered. There are a number of genetic variants that may reduce the risk of tonsillectomy by conferring a protective effect.
GWAS_EFO_0006809: docosapentaenoic acid measurement - The determination of the amount of docosapentaenoic acid present in a sample.
GWAS_EFO_0004695: intraocular pressure measurement - Is a quantification of intraocular pressure. Increased intraocular pressure is a heritable risk factor for primary open angle glaucoma.
GWAS_EFO_0001365: age-related macular degeneration - Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.|Age-related loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.|Degenerative changes in the macula lutea of the retina.
GWAS_EFO_0004526: mean corpuscular volume - A mean corpuscular volume is the result of calculation of the mean volume of erythrocytes in a blood sample.
GWAS_EFO_0009589: worry measurement - Quantification of whether an individual feels or felt worried.
GWAS_EFO_0004257: neurotic disorder - Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.|A form of functional mental illness that manifests in distressed emotional reactions such as anxiety, obsessive thoughts, compulsive behaviors, or irrational fears.
GWAS_EFO_0000729: ulcerative colitis - Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.|An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.
GWAS_EFO_0001645: coronary artery disease - Thickening and loss of elasticity of the CORONARY ARTERIES, leading to progressive arterial insufficiency (CORONARY DISEASE).|Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)|Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.|Narrowing of the coronary arteries due to fatty deposits inside the arterial walls.|An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.


#ENTITY MAPPING:
GENETIC ENTITIES AND THEIR ASSOCIATED GWAS:
Entity: Gene (ID: 16138618) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0010443, GWAS_EFO_0008579, GWAS_EFO_0004842, GWAS_EFO_0005090, GWAS_EFO_0004833, GWAS_EFO_0004980, GWAS_EFO_0004308, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0007869, GWAS_EFO_0008402, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0006335, GWAS_EFO_0000537, GWAS_EFO_0006336, GWAS_EFO_0004784, GWAS_EFO_0006335, GWAS_EFO_0004339, GWAS_EFO_0008579, GWAS_EFO_0000692, GWAS_EFO_0002690, GWAS_EFO_0005243, GWAS_EFO_0002690, GWAS_EFO_0001061, GWAS_EFO_0004509, GWAS_EFO_0007869, GWAS_EFO_0003778, GWAS_EFO_0007937, GWAS_EFO_0000274, GWAS_EFO_0000692, GWAS_EFO_0007924, GWAS_EFO_0006809, GWAS_EFO_0004695, GWAS_EFO_0001365, GWAS_EFO_0000274, GWAS_EFO_0004784, GWAS_EFO_0004526, GWAS_EFO_0004842, GWAS_EFO_0009589, GWAS_EFO_0007006, GWAS_EFO_0004257, GWAS_EFO_0007660, GWAS_EFO_0000729, GWAS_EFO_0004695, GWAS_EFO_0001645, GWAS_EFO_0004784, GWAS_EFO_0008354, GWAS_EFO_0004526
Entity: Transcript (ID: 16223570) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0010443, GWAS_EFO_0008579, GWAS_EFO_0004842, GWAS_EFO_0005090, GWAS_EFO_0004833, GWAS_EFO_0004980, GWAS_EFO_0004308, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0007869, GWAS_EFO_0008402, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0006335, GWAS_EFO_0000537, GWAS_EFO_0006336, GWAS_EFO_0004784, GWAS_EFO_0006335, GWAS_EFO_0004339, GWAS_EFO_0008579, GWAS_EFO_0000692, GWAS_EFO_0002690, GWAS_EFO_0005243, GWAS_EFO_0002690, GWAS_EFO_0001061, GWAS_EFO_0004509, GWAS_EFO_0007869, GWAS_EFO_0003778, GWAS_EFO_0007937, GWAS_EFO_0000274, GWAS_EFO_0000692, GWAS_EFO_0007924, GWAS_EFO_0006809, GWAS_EFO_0004695, GWAS_EFO_0001365, GWAS_EFO_0000274, GWAS_EFO_0004784, GWAS_EFO_0004526, GWAS_EFO_0004842, GWAS_EFO_0009589, GWAS_EFO_0007006, GWAS_EFO_0004257, GWAS_EFO_0007660
Entity: Transcript (ID: 16223588) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0010443, GWAS_EFO_0008579, GWAS_EFO_0004842, GWAS_EFO_0005090, GWAS_EFO_0004833, GWAS_EFO_0004980, GWAS_EFO_0004308, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0007869, GWAS_EFO_0008402, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0006335, GWAS_EFO_0000537, GWAS_EFO_0006336, GWAS_EFO_0004784, GWAS_EFO_0006335, GWAS_EFO_0004339, GWAS_EFO_0008579, GWAS_EFO_0000692, GWAS_EFO_0002690, GWAS_EFO_0005243, GWAS_EFO_0002690, GWAS_EFO_0001061, GWAS_EFO_0004509, GWAS_EFO_0007869, GWAS_EFO_0003778, GWAS_EFO_0007937, GWAS_EFO_0000274, GWAS_EFO_0000692, GWAS_EFO_0007924, GWAS_EFO_0006809, GWAS_EFO_0004695, GWAS_EFO_0001365, GWAS_EFO_0000274, GWAS_EFO_0004784, GWAS_EFO_0004526, GWAS_EFO_0004842, GWAS_EFO_0009589, GWAS_EFO_0007006, GWAS_EFO_0004257, GWAS_EFO_0007660
Entity: Transcript (ID: 16223603) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0010443, GWAS_EFO_0008579, GWAS_EFO_0004842, GWAS_EFO_0005090, GWAS_EFO_0004833, GWAS_EFO_0004980, GWAS_EFO_0004308, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0007869, GWAS_EFO_0008402, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0006335, GWAS_EFO_0000537, GWAS_EFO_0006336, GWAS_EFO_0004784, GWAS_EFO_0006335, GWAS_EFO_0004339, GWAS_EFO_0008579, GWAS_EFO_0000692, GWAS_EFO_0002690, GWAS_EFO_0005243, GWAS_EFO_0002690, GWAS_EFO_0001061, GWAS_EFO_0004509, GWAS_EFO_0007869, GWAS_EFO_0003778, GWAS_EFO_0007937, GWAS_EFO_0000274, GWAS_EFO_0000692, GWAS_EFO_0007924, GWAS_EFO_0006809, GWAS_EFO_0004695, GWAS_EFO_0001365, GWAS_EFO_0000274, GWAS_EFO_0004784, GWAS_EFO_0004526, GWAS_EFO_0004842, GWAS_EFO_0009589, GWAS_EFO_0007006, GWAS_EFO_0004257, GWAS_EFO_0007660
Entity: Transcript (ID: 16223660) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0010443, GWAS_EFO_0008579, GWAS_EFO_0004842, GWAS_EFO_0005090, GWAS_EFO_0004833, GWAS_EFO_0004980, GWAS_EFO_0004308, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0007869, GWAS_EFO_0008402, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869
Entity: Non Coding RNA (ID: 16961910) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0010443, GWAS_EFO_0008579, GWAS_EFO_0004842, GWAS_EFO_0005090, GWAS_EFO_0004833, GWAS_EFO_0004980, GWAS_EFO_0004308, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0007869, GWAS_EFO_0008402, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0006335, GWAS_EFO_0000537, GWAS_EFO_0006336, GWAS_EFO_0004784, GWAS_EFO_0006335, GWAS_EFO_0004339, GWAS_EFO_0008579, GWAS_EFO_0000692, GWAS_EFO_0002690, GWAS_EFO_0005243, GWAS_EFO_0002690, GWAS_EFO_0001061, GWAS_EFO_0004509, GWAS_EFO_0007869, GWAS_EFO_0003778, GWAS_EFO_0007937, GWAS_EFO_0000274, GWAS_EFO_0000692, GWAS_EFO_0007924, GWAS_EFO_0006809, GWAS_EFO_0004695, GWAS_EFO_0001365, GWAS_EFO_0000274, GWAS_EFO_0004784, GWAS_EFO_0004526, GWAS_EFO_0004842, GWAS_EFO_0009589, GWAS_EFO_0007006, GWAS_EFO_0004257, GWAS_EFO_0007660
Entity: TF Binding Site (ID: 103616505) -> Associated GWAS: GWAS_EFO_0000249
Entity: TF Binding Site (ID: 130863091) -> Associated GWAS: GWAS_EFO_0000249
Entity: TF Binding Site (ID: 133652592) -> Associated GWAS: GWAS_EFO_0000249
Entity: TF Binding Site (ID: 166278752) -> Associated GWAS: GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249
Entity: Histone Modification Site (ID: 81812569) -> Associated GWAS: GWAS_EFO_0000249
Entity: DNase Hypersensitivity Site (ID: 30106700) -> Associated GWAS: GWAS_EFO_0000249
Entity: ChromHMM State (ID: 19110302) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937
Entity: ChromHMM State (ID: 19699805) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0006335, GWAS_EFO_0000537, GWAS_EFO_0006336, GWAS_EFO_0004784, GWAS_EFO_0006335, GWAS_EFO_0004339, GWAS_EFO_0008579, GWAS_EFO_0000692, GWAS_EFO_0002690, GWAS_EFO_0005243
Entity: ChromHMM State (ID: 20259657) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708
Entity: ChromHMM State (ID: 20849570) -> Associated GWAS: GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180, GWAS_EFO_0004256, GWAS_EFO_0009584, GWAS_EFO_0002690, GWAS_EFO_0007006, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0007937, GWAS_EFO_0004875, GWAS_EFO_0008354, GWAS_EFO_0007869, GWAS_EFO_0001071, GWAS_EFO_0006527, GWAS_EFO_0000708, GWAS_EFO_0002690, GWAS_EFO_0008401
Entity: ChromHMM State (ID: 21458131) -> Associated GWAS: GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180
Entity: ChromHMM State (ID: 22086312) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000180
Entity: ChromHMM State (ID: 22682214) -> Associated GWAS: GWAS_EFO_0002690, GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249, GWAS_HP_0000155, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: chr_chain (ID: 286370) -> Associated GWAS: GWAS_EFO_0008401, GWAS_EFO_0007006, GWAS_EFO_0007937, GWAS_EFO_0007660, GWAS_EFO_0007869, GWAS_EFO_0004984, GWAS_EFO_0007984, GWAS_EFO_0007937, GWAS_EFO_0000249


#CLINVAR INFO:

CLINVAR PATHOGENICITY SUMMARY:
==============================
• Total ClinVar variants analyzed: 39487
• Pathogenic/Likely Pathogenic: 4000
• Benign/Likely Benign: 14323
• Uncertain Significance: 21144
• Other Classifications: 20
ASSOCIATED PHENOTYPES/DISEASES (NON-BENIGN VARIANTS):
====================================================
• Cardiovascular phenotype (n=12650)
• not provided|Cardiovascular phenotype (n=1997)
• Cardiovascular phenotype|not provided (n=1459)
• Ehlers-Danlos syndrome due to tenascin-X deficiency (n=1319)
• Vesicoureteral reflux 8 (n=1257)
• not provided|Cardiovascular phenotype|not specified (n=360)
• Cardiovascular phenotype|not specified (n=290)
• Ehlers-Danlos syndrome (n=281)
• Ehlers-Danlos syndrome|Cardiovascular phenotype (n=256)
• not provided|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=170)
• Vesicoureteral reflux 8|Cardiovascular phenotype (n=163)
• TNXB-related disorder (n=150)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=140)
• Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=130)
• Ehlers-Danlos syndrome|Cardiovascular phenotype|not provided (n=122)
• not provided|not specified (n=119)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype (n=102)
• not provided|Cardiovascular phenotype|TNXB-related disorder (n=79)
• not provided|not specified|Cardiovascular phenotype (n=74)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Vesicoureteral reflux 8 (n=67)
• not provided|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=65)
• Cardiovascular phenotype|Vesicoureteral reflux 8 (n=64)
• Vesicoureteral reflux 8|not provided|Cardiovascular phenotype (n=63)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|TNXB-related disorder|not specified (n=59)
• Cardiovascular phenotype|not provided|not specified (n=57)
• not provided|Vesicoureteral reflux 8 (n=56)
• not provided|Cardiovascular phenotype|Vesicoureteral reflux 8 (n=55)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype (n=52)
• not provided|TNXB-related disorder|Cardiovascular phenotype (n=49)
• not provided|TNXB-related disorder (n=49)
• Cardiovascular phenotype|not provided|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=47)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|not specified (n=46)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided (n=46)
• See cases (n=40)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome (n=40)
• Vesicoureteral reflux 8|TNXB-related disorder (n=40)
• Vesicoureteral reflux 8|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=39)
• not provided|not specified|Cardiovascular phenotype|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=39)
• Cardiovascular phenotype|TNXB-related disorder (n=37)
• Cardiovascular phenotype|not provided|TNXB-related disorder (n=36)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|Cardiovascular phenotype (n=35)
• Ehlers-Danlos syndrome|Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=33)
• TNXB-related disorder|Cardiovascular phenotype (n=32)
• not provided|TNXB-related disorder|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=32)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency|not specified (n=32)
• Ehlers-Danlos syndrome|Cardiovascular phenotype|not specified (n=31)
• Vesicoureteral reflux 8|Ehlers-Danlos syndrome|Cardiovascular phenotype (n=30)
• Inborn genetic diseases|not provided (n=30)
• not provided|Cardiovascular phenotype|Vesicoureteral reflux 8|Ehlers-Danlos syndrome (n=30)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=27)
• Cardiovascular phenotype|not specified|not provided (n=27)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|Vesicoureteral reflux 8|Cardiovascular phenotype|TNXB-related disorder (n=24)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome|Vesicoureteral reflux 8 (n=24)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|TNXB-related disorder|not specified (n=24)
• not specified|Cardiovascular phenotype (n=23)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|Vesicoureteral reflux 8 (n=23)
• Vesicoureteral reflux 8|Cardiovascular phenotype|not provided (n=23)
• Vesicoureteral reflux 8|Ehlers-Danlos syndrome|not specified|Vesicoureteral reflux 8 (n=22)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|not specified (n=21)
• Vesicoureteral reflux 8|not provided (n=20)
• not provided|Cardiovascular phenotype|TNXB-related disorder|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency|See cases|not specified (n=20)
• Vesicoureteral reflux 8|Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype (n=20)
• Vesicoureteral reflux 8|Vesicoureteral reflux 8|not specified (n=20)
• not provided|Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype (n=20)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|not provided (n=20)
• not provided|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency|not specified|Vesicoureteral reflux 8|Cardiovascular phenotype (n=18)
• not provided|See cases|TNXB-related disorder|Cardiovascular phenotype (n=18)
• not provided|not specified|Ehlers-Danlos syndrome|Cardiovascular phenotype (n=18)
• Ehlers-Danlos syndrome, type 3|Cardiovascular phenotype (n=18)
• not provided|Cardiovascular phenotype|TNXB-related disorder|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=18)
• not provided|Cardiovascular phenotype|not specified|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=16)
• not specified|not provided|Cardiovascular phenotype (n=16)
• TNXB-related disorder|Cardiovascular phenotype|not provided (n=14)
• not provided|not specified|Ehlers-Danlos syndrome|Cardiovascular phenotype|TNXB-related disorder (n=14)
• not provided|Cardiovascular phenotype|not specified|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=14)
• not provided|Vesicoureteral reflux 8|Cardiovascular phenotype (n=13)
• not provided|TNXB-related disorder|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|not specified (n=13)
• Ehlers-Danlos syndrome|not provided|Cardiovascular phenotype (n=13)
• not provided|Cardiovascular phenotype|TNXB-related disorder|not specified (n=13)
• Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided (n=13)
• Cardiovascular phenotype|not provided|Ehlers-Danlos syndrome|not specified (n=13)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|Vesicoureteral reflux 8|not specified (n=13)
• TNXB-related hypermobile Ehlers-Danlos syndrome (n=13)
• not provided|Vesicoureteral reflux 8|not specified|Cardiovascular phenotype (n=13)
• not provided|Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|Ehlers-Danlos syndrome|not specified (n=13)
• not specified|Ehlers-Danlos syndrome|Cardiovascular phenotype (n=13)
• Vesicoureteral reflux 8|Cardiovascular phenotype|not specified (n=13)
• Vesicoureteral reflux 8|not specified|Ehlers-Danlos syndrome (n=13)
• not provided|Ehlers-Danlos syndrome|TNXB-related disorder|Vesicoureteral reflux 8 (n=13)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Ehlers-Danlos syndrome due to tenascin-X deficiency|not specified|Cardiovascular phenotype (n=13)
• not provided|Ehlers-Danlos syndrome due to tenascin-X deficiency|Ehlers-Danlos syndrome|Vesicoureteral reflux 8 (n=13)
• Inborn genetic diseases|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=13)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|not specified|Vesicoureteral reflux 8|not provided (n=13)
• Ehlers-Danlos syndrome|Cardiovascular phenotype|Vesicoureteral reflux 8|not specified (n=13)
• Vesicoureteral reflux 8|not specified (n=13)
• Cardiovascular phenotype|TNXB-related disorder|not provided|Vesicoureteral reflux 8 (n=13)
• Inborn genetic diseases (n=13)
• Vesicoureteral reflux (n=13)
• not provided|TNXB-related disorder|Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|Vesicoureteral reflux 8 (n=13)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not specified|not provided (n=12)
• not provided|Ehlers-Danlos syndrome (n=12)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|TNXB-related disorder|Cardiovascular phenotype (n=12)
• not provided|not specified|Cardiovascular phenotype|TNXB-related disorder|Ehlers-Danlos syndrome (n=12)
• not provided|Cardiovascular phenotype|not specified|Ehlers-Danlos syndrome|TNXB-related disorder (n=12)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|not specified|TNXB-related disorder (n=12)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|Ehlers-Danlos syndrome|See cases|Cardiovascular phenotype (n=11)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|Ehlers-Danlos syndrome|Vesicoureteral reflux 8|Cardiovascular phenotype (n=11)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|TNXB-related disorder|not specified|Cardiovascular phenotype (n=11)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome|not specified (n=11)
• not specified|not provided (n=11)
• not provided|not specified|Ehlers-Danlos syndrome (n=11)
• Cardiovascular phenotype|TNXB-related disorder|not specified (n=10)
• not provided|Ehlers-Danlos syndrome|Vesicoureteral reflux 8|Cardiovascular phenotype|not specified|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=10)
• TNXB-related disorder|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=8)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency|TNXB-related disorder|Ehlers-Danlos syndrome|not specified (n=8)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome|TNXB-related disorder|not specified (n=8)
• Ehlers-Danlos syndrome|Cardiovascular phenotype|not specified|not provided (n=8)
• 7 conditions|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=8)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=8)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Vesicoureteral reflux 8|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=8)
• Vesicoureteral reflux 8|not specified|Cardiovascular phenotype|TNXB-related disorder (n=8)
• Cardiovascular phenotype|Vesicoureteral reflux 8|TNXB-related disorder (n=8)
• Ehlers-Danlos syndrome, type 3|not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|not specified|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=8)
• Ehlers-Danlos syndrome|Cardiovascular phenotype|TNXB-related disorder (n=8)
• not provided|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|TNXB-related disorder|not specified (n=7)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Cardiovascular phenotype|not specified|not provided (n=7)
• not provided|Cardiovascular phenotype|not specified|Vesicoureteral reflux 8 (n=7)
• not provided|Cardiovascular phenotype|Ehlers-Danlos syndrome|Ehlers-Danlos syndrome due to tenascin-X deficiency|not specified (n=7)
• 7 conditions|Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided (n=7)
• Cardiovascular phenotype|Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|not specified (n=7)
• Vesicoureteral reflux 8|not provided|TNXB-related disorder (n=6)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|Ehlers-Danlos syndrome (n=6)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|not provided|Vesicoureteral reflux 8 (n=6)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|TNXB-related disorder (n=6)
• Ehlers-Danlos syndrome|not provided (n=6)
• not provided|not specified|Vesicoureteral reflux 8 (n=6)
• Ehlers-Danlos syndrome|not provided|not specified (n=6)
• See cases|not provided (n=6)
• Ehlers-Danlos syndrome due to tenascin-X deficiency|Ehlers-Danlos syndrome|not specified (n=6)
• Ehlers-Danlos syndrome|not provided|Ehlers-Danlos syndrome due to tenascin-X deficiency (n=6)
• Cardiovascular phenotype|not provided|Vesicoureteral reflux 8 (n=6)
• See cases|Cardiovascular phenotype (n=6)
• not provided|Ehlers-Danlos syndrome|Cardiovascular phenotype|TNXB-related disorder (n=6)


